{"filings":[{"id":1499596,"accession_number":"0001193125-26-297525","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2026-07-07T20:27:16+00:00","items":["5.02"],"status":"ready","headline":"LifeStance Health appoints three new directors; Jeffrey Rhodes resigns from board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Rhodes resigned from board effective July 2, 2026; no disagreement with company.","Board appointed Thurman Justice, Lori Goltermann, and Safwan Shabab as directors.","Justice and Goltermann (Class II) serve until 2029 annual meeting; Shabab (Class III) until 2027.","Justice on audit and quality/compliance committees; Goltermann on compensation and nominating/governance; Shabab on nominating/governance.","Justice and Goltermann each received initial award of 35,492 RSUs (time-and performance-based, subject to continued service)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":862516,"accession_number":"0001193125-26-257606","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2026-06-04T20:46:54+00:00","items":["5.07"],"status":"ready","headline":"LifeStance Health annual meeting votes: directors elected, auditor ratified, say-on-pay approved.","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Bourdon and Robert Bessler elected as Class II directors with 244.97M/83.97M and 280.02M/48.92M for/withhold votes.","Ratification of PwC as auditor: 357.76M for, 209K against, 751K abstain.","Non-binding advisory say-on-pay vote passed: 322.90M for, 5.68M against, 354K abstain; 29.78M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":41761,"accession_number":"0001193125-26-219669","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2026-05-12T20:43:47+00:00","items":["8.01","9.01"],"status":"ready","headline":"LifeStance closes 35M share secondary offering; repurchases 6M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["35,000,000 shares sold by selling stockholders; company received no proceeds.","Company repurchased 6,000,000 shares from underwriter at same price as public offering.","Underwriter: J.P. Morgan Securities LLC; offering closed May 12, 2026.","All shares sold pursuant to effective shelf registration statement (Form S-3)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96156,"accession_number":"0001193125-26-209709","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeStance Q1 revenue up 21% to $403.5M; net income $14.2M; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $403.5M (+21% YoY); net income $14.2M vs $0.7M; Adjusted EBITDA $51.1M (+48%).","Clinician base up 11% to 8,349 (net +309); visit volumes up 18% to 2.5M.","Center Margin $135.9M (33.7% of revenue) vs $109.8M (33.0%).","FY2026 guidance raised: revenue $1.64B-1.68B, Adj EBITDA $200M-220M; Q2 rev $405M-425M.","Free cash flow $22.3M; cash $194.8M; net debt $262.5M."],"consensus_eps_estimate":0.0068,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":403476000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109822,"accession_number":"0001193125-26-102436","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"LifeStance promotes Lisa Miller to COO effective March 10, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lisa Miller, previously EVP Practice Operations, named Chief Operating Officer.","Annual base salary set at $485,000 with bonus target of 85% of base.","Equity target grant value of approx. $1.5M via time- and performance-based RSUs.","Miller holds MBA from Columbia and MSc in Neuroscience; prior COO at Invo Healthcare."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109821,"accession_number":"0001193125-26-085507","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LifeStance Health secondary offering of 25M shares by selling stockholders; company to repurchase 7M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 25,000,000 shares of common stock by selling stockholders; company receives no proceeds.","Company agreed to repurchase 7,000,000 shares from underwriter at same price paid by underwriter.","Offering closed on March 2, 2026; underwritten by J.P. Morgan Securities LLC.","Underwriting agreement filed as Exhibit 1.1; legal opinion from Ropes & Gray filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109820,"accession_number":"0001193125-26-067858","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"LifeStance Q4 revenue $382M (+17% YoY); net income $11.7M; $100M buyback; Chairman transition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $382.2M (+17% YoY); full-year revenue $1.42B (+14% YoY).","Q4 net income $11.7M vs loss $7.1M; full-year net income $9.7M vs loss $57.4M.","Adjusted EBITDA Q4 $48.8M (+49% YoY); full-year $157.7M (+32% YoY).","2026 guidance: revenue $1.615B-$1.655B; Adjusted EBITDA $185M-$205M.","Board approved $100M share repurchase; Kenneth Burdick transitions to non-executive Chairman effective Mar 16, 2026."],"consensus_eps_estimate":-0.0017,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1424285000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126364,"accession_number":"0001193125-25-267443","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeStance Q3 revenue $363.8M (+16% YoY), net income $1.1M; raises FY2025 adjusted EBITDA guidance to $146-152M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $363.8M vs $312.7M YoY (+16%); net income $1.1M vs net loss of $6.0M.","Adjusted EBITDA $40.2M, up 31% YoY; margin 11.1% vs 9.8%.","Clinician base grew 11% to 7,996; visit volumes +17% to 2.3M.","FY2025 guidance raised: Center Margin $448-462M, Adjusted EBITDA $146-152M.","Free cash flow positive $17.0M; cash balance $203.9M."],"consensus_eps_estimate":-0.0122,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1042090000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143122,"accession_number":"0001193125-25-186460","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"LifeStance board member William Miller resigns; Sarah Personette appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Miller resigned from the Board and all committees effective Aug 19, 2025, with no disagreement.","Sarah Personette appointed as director effective Aug 20, 2025.","Personette receives initial award of 74,766 RSUs vesting over time and performance, subject to continued service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143121,"accession_number":"0000950170-25-104363","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeStance Q2 revenue $345.3M (+11% YoY); raises FY 2025 Adj. EBITDA guidance to $140-150M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $345.3M (+11% YoY); net loss narrowed to $3.8M from $23.3M.","Adjusted EBITDA of $34.0M (+19% YoY); Free Cash Flow of $56.6M, a quarterly record.","Clinician base grew 11% to 7,708 (net +173 in Q2); visit volumes up 12% to 2.2M.","FY 2025 guidance: Adj. EBITDA raised to $140-150M (midpoint +$5M); revenue reiterated $1.40-1.44B.","Q3 2025 guidance: revenue $345-365M, Adj. EBITDA $33-39M, Center Margin $105-119M."],"consensus_eps_estimate":-0.0306,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":678281000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161223,"accession_number":"0001193125-25-136309","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LifeStance shareholders elect three Class I directors, ratify PwC, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Teresa DeLuca (292M for), Katherine Wood (245M for), Eric Palmer (318M for) elected to three-year terms.","Ratification of PricewaterhouseCoopers as auditor for FY2025 passed with ~346M votes for.","Advisory say-on-pay proposal approved with ~296M for vs ~27M against (excluding broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161222,"accession_number":"0001193125-25-119479","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"LifeStance appoints Vaughn Paunovich as CTO; CDO Pantaleoni to depart July 1","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vaughn Paunovich appointed CTO effective June 9, 2025; previously EVP at Amwell and CIO of Optum Health.","Pablo Pantaleoni (Chief Digital Officer) to depart July 1, 2025; receives severance including base salary and 12 months COBRA.","Pantaleoni's separation agreement includes accelerated vesting of RSUs after Jan 1, 2026 and restrictive covenants.","Paunovich will lead technology strategy to improve patient and clinician digital experience for mental health care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161221,"accession_number":"0000950170-25-064745","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeStance Q1 revenue $333M (+11%), first positive net income as public company","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $333M (+11% YoY); net income $0.7M vs net loss $21.1M in Q1 2024.","Adjusted EBITDA $34.6M (+25% YoY); Center Margin $109.8M (33.0% of revenue).","Clinician base grew to 7,535 (+10% YoY); visit volumes 2.1M (+10%).","FY 2025 guidance reaffirmed: revenue $1.40B-$1.44B, Adj EBITDA $130M-$150M.","Q2 2025 guidance: revenue $332M-$352M, Adj EBITDA $28M-$34M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":332970000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179382,"accession_number":"0001193125-25-037533","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"LifeStance appoints Dave Bourdon as CEO; Ken Burdick becomes Executive Chairman; Ryan McGroarty named CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dave Bourdon, CFO since 2022, becomes CEO effective March 3, 2025; Ryan McGroarty appointed CFO effective March 17, 2025.","Ken Burdick retires as CEO and becomes Executive Chairman, continuing on the Board.","Bourdon's new annual base salary is $700,000; target bonus 100% of salary for 2025.","McGroarty receives $550,000 base salary, $570,000 signing bonus, and $5M target equity award (RSUs and PSUs).","Both appointments follow nine consecutive quarters of meeting or exceeding financial expectations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179381,"accession_number":"0000950170-25-028099","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeStance Q4 revenue $325.5M (+16% YoY); 2025 EBITDA guidance $130-150M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $325.5M (+16% YoY); full year $1.251B (+19% YoY).","Net loss narrowed to $7.1M in Q4 vs $45.0M prior; full year $57.4M vs $186.3M.","Adjusted EBITDA Q4 $32.8M (+62% YoY); full year $119.7M (+103% YoY).","2025 guidance: revenue $1.40B-$1.44B, Center Margin $440M-$464M, Adj. EBITDA $130M-$150M.","Free cash flow $85.7M for 2024; cash $154.6M, net long-term debt $279.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1250970000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196083,"accession_number":"0001193125-24-282043","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["1.01","1.02","2.03"],"status":"ready","headline":"LifeStance enters new $290M term loan and $100M revolver, repays existing facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New senior secured term loan of $290M funded on Dec 19, 2024; revolving facility commitments of $100M available.","Both facilities mature on fifth anniversary of closing (Dec 2029).","Interest: SOFR + 3.00% (or base + 2.00%) with leverage-based stepdowns; undrawn commitment fee 0.45% p.a.","Proceeds used to repay all outstanding loans under prior credit agreement (dated May 2022), which was terminated.","Obligations guaranteed by Holdings and subsidiaries, secured by substantially all assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196082,"accession_number":"0000950170-24-122575","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeStance Q3 revenue $312.7M (+19% YoY); raises FY2024 guidance on Adj. EBITDA to $105-115M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $312.7M (+19% YoY); net loss improved to $6.0M from $61.6M; Adjusted EBITDA $30.7M (+110%).","Clinician base 7,269 (+13% YoY); visit volumes 2.0M (+15%); Center Margin $100.4M (32.1% of revenue, +32%).","FY2024 guidance raised: revenue $1.228B-$1.248B; Adj. EBITDA $105M-$115M; positive Free Cash Flow reiterated.","Q4 2024 guidance: revenue $302.5M-$322.5M; Adj. EBITDA $18M-$28M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":925490000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212343,"accession_number":"0000950170-24-093114","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeStance Q2 revenue up 20% to $312M; raises FY2024 guidance on strong margins","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $312.3M (+20% YoY); net loss narrowed to $23.3M from $45.5M; Adjusted EBITDA $28.6M (+103%).","Center Margin improved to 31.3% of revenue (28.1% prior year); clinician base up 14% to 6,984.","FY2024 guidance raised: revenue $1.2B-$1.242B, Adjusted EBITDA $90M-$100M; expects positive free cash flow.","Q3 2024 guidance: revenue $290M-$310M, Adjusted EBITDA $15M-$21M.","Cash $87M, net debt $279.5M; operating cash flow $44.1M in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":612768000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212342,"accession_number":"0001193125-24-175071","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"LifeStance President & COO Danish Qureshi terminated; receives 18-month salary continuation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Danish Qureshi's employment as President and COO terminated effective June 30, 2024.","He receives 18 months base salary continuation under separation agreement.","Outstanding equity awards eligible to vest for 18 months post-termination; options exercisable for 27 months.","Company equity subject to transfer restrictions for one year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231282,"accession_number":"0001193125-24-154291","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LifeStance Health stockholders elect directors, ratify auditor, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected three Class III directors: Kenneth Burdick, Jeffrey Rhodes, William Miller with majority broker non-votes.","Ratified PricewaterhouseCoopers LLP as independent auditor for FY2024 (339.8M for, 0.4M against).","Approved non-binding advisory vote on executive compensation (282.1M for, 50.8M against).","Approved annual frequency for future say-on-pay votes; Board adopted annual advisory vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231281,"accession_number":"0001193125-24-146587","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LifeStance announces secondary offering of 20M shares by selling stockholders; no proceeds to company","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriting agreement signed May 21 for 20M shares (plus 3M option) sold by selling stockholders.","Company receives no proceeds; all shares offered by existing stockholders, including option shares.","Underwriters led by Morgan Stanley and Goldman Sachs; closing expected May 24, 2024.","Offering made under automatically effective Form S-3 registration statement filed same day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231280,"accession_number":"0000950170-24-056089","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"LifeStance Q1 revenue +19% to $300.4M; raises FY2024 EBITDA guidance; COO to depart June 30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $300.4M (+19% YoY); net loss narrowed to $21.1M from $34.2M.","Adjusted EBITDA $27.7M (9.2% of revenue), up from $10.1M; FY2024 Adjusted EBITDA guidance raised to $88–$98M.","Clinician base grew 15% to 6,866; visit volumes up 15% to 1.9M; Center Margin $94.7M (31.5% of revenue).","President & COO Danish Qureshi notified departure effective June 30, 2024.","Q2 2024 guidance: revenue $297–$315M, Adjusted EBITDA $20–$26M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":300437000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249695,"accession_number":"0000950170-24-029684","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"LifeStance Health appoints Teresa DeLuca to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board appointed Teresa DeLuca as a director effective March 12, 2024.","No departures or other board changes announced.","Appointment fills a board vacancy or adds new director; no material compensation terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249694,"accession_number":"0000950170-24-021511","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeStance Q4 revenue $280.6M (+22% YoY); net loss $45M; guides FY24 revenue $1.19-$1.24B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $280.6M (+22% YoY); full-year revenue $1,055.7M (+23%).","Q4 net loss $45.0M; full-year net loss $186.3M. Adjusted EBITDA $20.3M (Q4) and $59.0M (FY).","Added 227 net clinicians in Q4, 1,014 in FY; total clinicians 6,645 (+18% YoY).","FY2024 guidance: revenue $1.19-$1.24B, Center Margin $345-$365M, Adj. EBITDA $80-$90M, positive free cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1055665000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249693,"accession_number":"0001193125-24-022199","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"LifeStance receives final court approval for $50M settlement; pays second $25M early","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Final approval granted Jan 30, 2024 for $50M class action settlement (Nayani v. LifeStance).","LifeStance paid both $25M installments in Q4 2023; $20M of first payment covered by insurance.","Drew $33M from credit facilities in Q4; ended 2023 with $79M cash and $290M long-term debt.","Preliminary Q4/FY 2023 financial data disclosed but no specific revenue or EPS figures provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267152,"accession_number":"0000950170-23-060505","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeStance Q3 revenue up 21% to $262.9M, net loss widens to $61.6M, raises FY guidance midpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $262.9M (+21% YoY); clinicians up 18% to 6,418 with record organic recruiting.","Net loss $61.6M vs $37.9M, driven by class action settlement and stock-based comp.","Adjusted EBITDA $14.6M (5.6% of revenue) vs $15.4M (7.1%) last year.","Raising FY 2023 guidance: revenue $1.03-1.04B, Center Margin $292-300M, Adjusted EBITDA $56-60M.","Q4 2023 outlook: revenue $255-265M, Center Margin $73-81M, Adjusted EBITDA $17-21M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":775062000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284423,"accession_number":"0000950170-23-040033","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeStance Q2 revenue up 24% to $259.6M; raises FY revenue guidance to $1.01-1.04B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $259.6M (+24% YoY); net loss $45.5M improved from $68.7M loss.","Adjusted EBITDA $14.1M (-3% YoY); Center Margin $73.0M (28.1% of revenue).","Total clinicians 6,132 (+17% YoY); net add 171 in Q2.","FY 2023 revenue guidance raised to $1.01-1.04B; reaffirms Adj. EBITDA $50-62M.","Q3 2023 guidance: revenue $250-260M, Adj. EBITDA $11-17M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":512167000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304118,"accession_number":"0001193125-23-159318","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LifeStance annual meeting elects directors, ratifies PwC as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Darren Black, Eric Shuey, and Robert Bessler elected Class II directors; each received >252M votes in favor.","Ratification of PwC as independent auditor for FY 2023 approved with 325.3M for, 81k against, 286k abstain.","Broker non-votes of 28.97M were recorded on the director election proposal.","All three director nominees and auditor ratification passed with substantial shareholder support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304117,"accession_number":"0000950170-23-019901","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeStance Q1 rev $252.6M (+24% YoY), net loss narrows to $34.2M; raises FY rev guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $252.6M (+24% YoY); Center Margin $69.6M (27.6% of revenue, +28% YoY).","Net loss $34.2M vs $62.3M loss; Adj EBITDA $10.1M vs $12.5M (down 19%).","FY 2023 revenue guidance raised to $990M-$1.02B; Center Margin $274-$290M; Adj EBITDA reaffirmed $50-$62M.","Q2 2023 guidance: rev $250-$260M, Center Margin $69-$76M, Adj EBITDA $10-$16M.","Clinicians 5,961 (+19% YoY, net add 330); cash $68.3M, net debt $224.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":252589000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323791,"accession_number":"0000950170-23-006541","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["2.02","5.03","7.01","9.01"],"status":"ready","headline":"LifeStance Q4 revenue $229.4M (+21% YoY); net loss $46.7M; 2023 rev guidance $980M-$1.02B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $229.4M (+21% YoY), full year revenue $859.5M (+29% YoY).","Q4 net loss $46.7M, full year net loss $215.6M; adjusted EBITDA Q4 $10.2M (4.4% margin), full year $52.7M (6.1% margin).","Clinician base grew 18% to 5,631; added 200 net clinicians in Q4.","2023 guidance: revenue $980M-$1.02B, Center Margin $270-290M, Adjusted EBITDA $50-62M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341789,"accession_number":"0000950170-22-023246","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeStance Q3 rev +25% to $217.6M; cuts FY22 guidance on lower visits, higher health costs; CEO/CFO changes","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $217.6M (+25% YoY); net loss $37.9M vs $120.5M loss; Adjusted EBITDA $15.4M (+44%).","Full-year 2022 guidance lowered: revenue $845-850M, Center Margin $229-232M, Adjusted EBITDA $50-53M.","Ken Burdick appointed Chairman & CEO effective Sept 7, succeeding Michael Lester (remains strategic advisor).","CFO transition: J. Michael Bruff to Business Transformation Officer; David Bourdon to become CFO Nov 10.","Ended Q3 with $90.3M cash, $212.0M net debt; total clinicians 5,431 (+24% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":630182000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341788,"accession_number":"0001193125-22-276872","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"LifeStance appoints David Bourdon as CFO, J. Michael Bruff to Business Transformation Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Bourdon appointed CFO effective Nov 10, 2022; succeeds J. Michael Bruff who becomes Business Transformation Officer.","Bourdon's annual base salary $500k, target bonus 75% of base, $1M stock signing bonus subject to repayment before 4-year anniversary.","Bourdon granted option to purchase 1.25M shares of LFST common stock; 1/3 time-based vesting over 4 years, 2/3 performance-based.","Bruff transition: retains $1.5M sign-on bonus, surrenders ~$1M in shares, accelerated vesting of RSUs and RSAs on effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358647,"accession_number":"0001193125-22-240642","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2022-09-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"LifeStance appoints Ken Burdick as CEO/Chairman; founding CEO Michael Lester retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ken Burdick appointed CEO and Chairman effective Sept 7, 2022; succeeds Michael Lester who retires as officer and director.","Danish Qureshi named President in addition to his role as COO.","Lester's Alert5 Consulting LLC receives $50,933.33/month consulting fee through Sept 7, 2023.","Burdick gets $700,000 base salary, target bonus 100% of base, and option for 9,404,539 shares with time/performance vesting.","Qureshi receives option for 2,821,362 shares with one-third time-based and two-thirds performance-based vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358646,"accession_number":"0000950170-22-016085","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeStance Q2 revenue $209.5M (+31%); net loss $68.7M; lowers FY revenue guidance to bottom of $865-885M range","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $209.5M, +31% YoY; net loss $68.7M (incl $57.5M stock comp).","Adjusted EBITDA $14.6M flat YoY; Center Margin $59.8M (28.5% of rev).","Clinicians 5,226 (+31%); net add 237 in Q2; 4 acquisitions closed.","FY2022 rev guidance lowered to bottom of $865-885M; Adj. EBITDA reaffirmed $63-67M; Q3 rev $216-221M.","Danish Qureshi appointed COO effective July 1; OBIE online booking live in 9 states."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":412622000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377406,"accession_number":"0001193125-22-166233","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"LifeStance shareholders elect directors, ratify PwC as auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors Jeffrey Crisan, Katherine Wood, and Seema Verma to Class I for three-year terms; each received >275M votes 'for'.","Ratified PricewaterhouseCoopers LLP as independent auditor for FY2022 with 312,861,031 votes for, 49,684 against.","No other proposals were considered at the annual meeting held June 1, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377405,"accession_number":"0001193125-22-158553","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2022-05-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"LifeStance draws new term loan, repays and terminates prior credit agreement","summary_kind":"llm","event_type":"debt","confidence":"low","bullets":["Drew term loan on May 16, 2022; proceeds used to repay all loans under May 2020 Credit Agreement.","All obligations under prior credit agreement released, liens terminated, prepayment fee paid.","Term loan draw previously disclosed in Form 8-K filed May 9, 2022; no new amounts provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377404,"accession_number":"0001193125-22-157550","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2022-05-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"LifeStance COO Gwen Booth retiring July 1, 2022; Danish Qureshi promoted to succeed her","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gwen Booth retires as COO effective July 1, 2022; will consult for $13,750/month and lead LifeStance Health Foundation.","Danish Qureshi, formerly Chief Growth Officer, appointed COO effective July 1, 2022, by Board on May 20.","Booth's RSUs modified to vest one-third at first anniversary, two-thirds at second; transfer restrictions extended.","Booth executed a separation agreement including a release of claims in favor of LifeStance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377403,"accession_number":"0000950170-22-008508","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["1.01","2.02","2.03","7.01","9.01"],"status":"ready","headline":"LifeStance Q1 rev +42% to $203.1M, net loss $62.3M on stock comp; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $203.1M (+42% YoY); net loss $62.3M (vs. $8.7M loss) driven by $59.9M stock-based comp.","Adjusted EBITDA flat at $12.5M; Center Margin $54.2M (26.7% of rev, down from 30.7%).","Total clinicians 4,989 (+51% YoY), net add of 199 in Q1; two acquisitions and 41 de novo centers.","New $350M credit facility: $200M term loan, $100M delayed draw, $50M revolver; matures 2027-2028.","Q2 2022 guidance: rev $209-214M, Center Margin $57-61M, Adj. EBITDA $12-15M; full-year reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":203095000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395801,"accession_number":"0000950170-22-003370","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeStance Q4 revenue $190.1M (+61% YoY); net loss $108M; 2022 guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2021 revenue $667.5M (+77% YoY); net loss $307.2M largely from stock-based compensation.","Q4 Adjusted EBITDA $11.4M (6.0% of revenue), down 31% YoY; full-year Adjusted EBITDA $49.2M (7.4% of revenue).","Clinician base grew 55% to 4,790; 415 net adds in Q4 and 1,693 for the full year.","2022 guidance: revenue $865-885M, Center Margin $240-255M, Adjusted EBITDA $63-67M.","Q1 2022 revenue expected $195-200M; Omicron impact estimated at $3-7M; de novo openings moderated to 80-90."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":414642,"accession_number":"0000950170-21-003476","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2021-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeStance Q3 revenue $173.8M (+70% YoY); net loss $120.5M on stock comp; FY revenue guided to lower end of $668-678M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $173.8M, up 70% YoY; Center Margin $52.1M (29.9% of revenue), up 57%.","Net loss $120.5M vs $3.3M loss a year ago, primarily driven by $120.7M stock/unit-based compensation.","Adjusted EBITDA $10.7M (6.2% of revenue), down 29% YoY from $15.0M.","Clinicians grew 72% to 4,375; added 400 net clinicians in Q3; retention stabilized ~80% annualized.","FY 2021 revenue expected toward lower end of $668-678M range; Center Margin and Adjusted EBITDA guidance unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":477516000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":432736,"accession_number":"0001193125-21-256918","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2021-08-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Seema Verma appointed to LifeStance Board of Directors; receives 79,543 RSU award","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Seema Verma appointed as director effective August 22, 2021.","Initial award of 79,543 restricted stock units granted under the 2021 Equity Incentive Plan.","RSUs vest based on time and performance conditions, subject to continued board service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":432735,"accession_number":"0000950170-21-001270","cik":1845257,"company_name":"LifeStance Health Group, Inc.","ticker":"LFST","form_type":"8-K","filed_at":"2021-08-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"LifeStance Health Q2 revenue $160.5M (+91% YoY), initiates FY2021 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $160.5M, up 91% YoY; net loss $70M includes $29.5M stock comp and $10M foundation endowment.","Adjusted EBITDA $14.5M (+39% YoY); total clinicians 3,975, up 94% YoY.","IPO completed June 10, net proceeds $548.9M used to retire debt and for corporate purposes.","FY2021 guidance: revenue $668M-$678M, Center Margin $198M-$208M, Adjusted EBITDA $47M-$53M.","Opened 35 de novo centers, entered 5 new states, completed 10 acquisitions in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":303681000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2994081945.3771353,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}